Toward Cure Chronic Hepatitis B Infection and Hepatocellular Carcinoma Prevention: Lessons Learned From Nucleos(T)Ide Analogues Therapy

Toward Cure Chronic Hepatitis B Infection and Hepatocellular Carcinoma Prevention: Lessons Learned From Nucleos(T)Ide Analogues Therapy Publisher Pubmed

Tavakolpour S^{1, 2, 3} ; Mirsafaei HS² ; Elkaei Behjati S¹ ; Ghasemiadl M¹ ; Akhlaghdoust M⁴ ; Sali S¹

Show Affiliations

1. Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2. Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran
3. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
4. Pars Advanced and Minimally Invasive Manners Research Center, Pars Hospital, Tehran, Iran

Source: Immunology Letters Published:2017

Abstract

Nucleos(t)ide analogues (NAs) could successfully suppress hepatitis B virus (HBV) replication in patients with chronic hepatitis B (CHB). However, due to probable development of drug resistance or low/delayed response, these treatments may not be satisfactory. In addition to the HBV DNA polymerase inhibiting activity, these drugs could lead to changes in cytokines profiles. It is important to monitor these changes so that they could be used as target of treatment. Evaluating the previously reported immune responses due to NAs treatments, it was concluded that interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), interleukin-4 (IL-4), and IL-12 increase after the treatment. This will be followed by the improved capacity of immune cells for eliminating HBV. In contrast, regulatory responses including IL-10 and transforming growth factor-beta (TGF-β) significantly decreased as the result of NAs therapy. Unexpectedly, T helper (Th) 17-associated cytokines also decreased significantly. These results could be used to employ the new strategies to suppress viral replication, minimize HBV DNA levels, inducing hepatitis B e antigen (HBeAg) seroconversion or even hepatitis B surface antigen (HBsAg) seroclearance. In order to accomplish these goals, extended treatment with high dose of both IL-12 and IFN in combination with high barrier to resistance NA might significantly improve the HBsAg seroclearance rate. Considering the danger of emerging aberrant immune responses, determining the optimum dosage as well as close monitoring of patients during the treatment is strongly advised. In order to make HBV immunotherapy practical, further studies are needed to confirm these results. © 2017 European Federation of Immunological Societies

Related Docs

View other Related Docs

1. The Possible Role of Interleukin-35 and Its Therapeutic Potential in Pemphigus, International Immunopharmacology (2017)

2. Towards Personalized Medicine for Patients With Autoimmune Diseases: Opportunities and Challenges, Immunology Letters (2017)

3. Hepatitis B Immunopathogenesis and Immunotherapy, Immunotherapy (2016)

4. Pemphigus Trigger Factors: Special Focus on Pemphigus Vulgaris and Pemphigus Foliaceus, Archives of Dermatological Research (2018)

5. The Dual Nature of Retinoic Acid in Pemphigus and Its Therapeutic Potential: Special Focus on All-Trans Retinoic Acid, International Immunopharmacology (2016)

6. Il-17 and Il-22 Genetic Polymorphisms in Hbv Vaccine Non- and Low-Responders Among Healthcare Workers, GERMS (2016)

7. Pathogenic and Protective Roles of Cytokines in Pemphigus: A Systematic Review, Cytokine (2020)

8. Features and Roles of T Helper 9 Cells and Interleukin 9 in Immunological Diseases, Allergologia et Immunopathologia (2019)

Experts (# of related papers)

View all Related Experts

Maryam Daneshpajooh (3)

Hamid Reza Mahmoodi (3)

Style	Citing Format
MLA	Tavakolpour S, et al.. "Toward Cure Chronic Hepatitis B Infection and Hepatocellular Carcinoma Prevention: Lessons Learned From Nucleos(T)Ide Analogues Therapy." Immunology Letters, vol. 190, no. , 2017, pp. 206-212.
APA	Tavakolpour S, Mirsafaei HS, Elkaei Behjati S, Ghasemiadl M, Akhlaghdoust M, Sali S (2017). Toward Cure Chronic Hepatitis B Infection and Hepatocellular Carcinoma Prevention: Lessons Learned From Nucleos(T)Ide Analogues Therapy. Immunology Letters, 190(), 206-212.
Chicago	Tavakolpour S, Mirsafaei HS, Elkaei Behjati S, Ghasemiadl M, Akhlaghdoust M, Sali S. "Toward Cure Chronic Hepatitis B Infection and Hepatocellular Carcinoma Prevention: Lessons Learned From Nucleos(T)Ide Analogues Therapy." Immunology Letters 190, no. (2017): 206-212.
Harvard	Tavakolpour S et al. (2017) 'Toward Cure Chronic Hepatitis B Infection and Hepatocellular Carcinoma Prevention: Lessons Learned From Nucleos(T)Ide Analogues Therapy', Immunology Letters, 190(), pp. 206-212.
Vancouver	Tavakolpour S, Mirsafaei HS, Elkaei Behjati S, Ghasemiadl M, Akhlaghdoust M, Sali S. Toward Cure Chronic Hepatitis B Infection and Hepatocellular Carcinoma Prevention: Lessons Learned From Nucleos(T)Ide Analogues Therapy. Immunology Letters. 2017;190():206-212.
BibTex	@article{ author = {Tavakolpour S and Mirsafaei HS and Elkaei Behjati S and Ghasemiadl M and Akhlaghdoust M and Sali S}, title = {Toward Cure Chronic Hepatitis B Infection and Hepatocellular Carcinoma Prevention: Lessons Learned From Nucleos(T)Ide Analogues Therapy}, journal = {Immunology Letters}, volume = {190}, number = {}, pages = {206-212}, year = {2017} }
RIS	TY - JOUR AU - Tavakolpour S AU - Mirsafaei HS AU - Elkaei Behjati S AU - Ghasemiadl M AU - Akhlaghdoust M AU - Sali S TI - Toward Cure Chronic Hepatitis B Infection and Hepatocellular Carcinoma Prevention: Lessons Learned From Nucleos(T)Ide Analogues Therapy JO - Immunology Letters VL - 190 IS - SP - 206 EP - 212 PY - 2017 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract